The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05085327
Recruitment Status : Completed
First Posted : October 20, 2021
Results First Posted : March 25, 2024
Last Update Posted : March 25, 2024
Sponsor:
Information provided by (Responsible Party):
HALEON

Brief Summary:
The purpose of this study is to determine the static SPF of three sunscreen products (ChapStick Lip Moisturizer [CLM] Original, CLM Mint Flavour and CLM Black Cherry Flavour) using the methodology described in the Food and Drug Administration (FDA) Final Rule (2011).

Condition or disease Intervention/treatment Phase
Sunscreening Agents Drug: ChapStick Lip Moisturizer Original Drug: ChapStick Lip Moisturizer Mint Drug: ChapStick Lip Moisturizer Black Cherry Drug: SPF Standard Sunscreen Not Applicable

Detailed Description:
A single-center, randomized, controlled, intra-individual comparison, evaluator-blind, clinical study to determine the SPF of three sunscreen lip balms. Each participant will evaluate the three test products, an SPF standard and no treatment. Study treatments will be randomly assigned to 5 test sites delineated on the skin of the participant's back. Test sites will be exposed to doses of ultraviolet (UV) radiation and erythemal response evaluated 16-24 hours later. Minimal erythema dose (MED) will be determined for protected and unprotected sites and used to determine the SPF value of each test product.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Only the outcomes (erythema) assessor is blinded to treatment allocation
Primary Purpose: Treatment
Official Title: Clinical Evaluation of the Sun Protection Factor (SPF) of Sunscreen Products According to the FDA Final Rule: Sunscreen Drug Products (2011)
Actual Study Start Date : October 19, 2021
Actual Primary Completion Date : November 4, 2021
Actual Study Completion Date : November 4, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sun Exposure

Arm Intervention/treatment
Experimental: ChapStick Lip Moisturizer Original
Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
Drug: ChapStick Lip Moisturizer Original
Sunscreen lip balm.

Experimental: ChapStick Lip Moisturizer Mint
Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Mint will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
Drug: ChapStick Lip Moisturizer Mint
Sunscreen lip balm.

Experimental: ChapStick Lip Moisturizer Black Cherry
Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Black Cherry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
Drug: ChapStick Lip Moisturizer Black Cherry
Sunscreen lip balm.

Active Comparator: SPF Standard
Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
Drug: SPF Standard Sunscreen
SPF Standard (7 percent [%] Padimate-O and 3% Oxybenzone)




Primary Outcome Measures :
  1. Arithmetic Mean SPF Values [ Time Frame: From 16 to 24 hours post UV exposure ]
    SPF values for each test product and the SPF standard were first calculated for each individual participant: SPFi = MEDp/MEDuR (p=protected [treated] site; u=unprotected [untreated] site). The arithmetic mean SPF, standard deviation (SD) and standard error (SE) were then calculated separately for each test product and the SPF standard from valid SPFi data: SPF = (∑SPFi)/n; SD = √[(∑SPFi^2) - ((∑SPFi)^2/n) / (n-1))]; SE = SD/√n (n = no. participants providing valid test results). For SPF determination to be considered valid, in compliance with FDA Final Rule 2011, the mean SPF value of the SPF standard should fall within the SD range of the expected SPF (i.e.,16.3 ± 3.43 or 12.87 to 19.73). The MED is the lowest dose of UV radiation that produces the first perceptible erythema with clearly defined borders (covering more than 50% of the exposure site), 16 to 24 hours (hrs) after UV exposure administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant must provide a signed and dated, legally effective, informed consent document, which indicates they have been informed of all pertinent aspects of the study, before any study procedures are performed.
  • Participant must provide relevant details of their medical history and current/recent medications and treatments (self-reported).
  • Participant must have completed an annual Health Insurance Portability and Accountability Act (HIPAA) Authorization form.
  • Participant must have completed a Photo Release Form.
  • Participant must be able to read, write, speak and understand English.
  • Participant must be in good general health.
  • Participant must have uniform skin color over the test area (skin of the back between the shoulder blades and above the waistline) and an Individual Typology Angle (ITA) value more than (>)28 degree.
  • Participant must have Fitzpatrick Skin Type I, II or III
  • Participant must have sufficient area of suitable skin on their back for at least six 40 centimeter square (cm^2) test sites.
  • Willing to have body hair clipped by a technician if participant has excessive hair in the test area.
  • Participant must have a valid form of personal identification (photo identity [ID], driver's license, passport, permanent resident card, military ID card; forms cannot be expired).
  • Male and female participants of child-bearing potential must agree to use a highly effective method of contraception for the duration of the study and for 14 days after their last treatment application. (Note: Note: A participant is considered to be of child-bearing potential if, in the opinion of the Principle Investigator (PI), they are biologically capable of having children and sexually active.

Exclusion Criteria:

  • Participant with a scheduled or planned Covid-19 vaccination during likely dates of study participation.
  • Participant with a history of abnormal response to sunlight/UV radiation.
  • Participant with a history of sensitivity to any ingredient of the test material or skin marker pen, or to latex; or any known sensitivities/allergies, including but not limited to cosmetic/toiletry products and topically applied skin treatment products/drugs.
  • Participant with any significant dermatological condition, such as atopic dermatitis (eczema), psoriasis, skin cancer, melanoma, active dermal lesions, nevi, blemishes or moles, lupus, diabetes, or connective tissue disease, that would increase the risk associated with participation. (Note: presence of non-dysplastic nevi, blemishes, or moles would be acceptable if, in the opinion of the PI, they will neither jeopardize participant safety or compromise study outcomes. A participant with dysplastic nevi should be disqualified.
  • Participant receiving any treatment with medications that would, in the opinion of the PI, confound study outcomes or increase the risk associated with participation, such as systemic or topical corticosteroids, antibiotics, anti-inflammatory drugs, antihistamines, antihypertension medications, or any other photosensitive medications. (Note: The prohibited medication list will be available to site staff for reference during screening)
  • Participant who has used topical or systemic steroids, antihistamines, antibiotics or anti-inflammatory medications within 7 days of Study Day 1 which, in the opinion of the PI, could interfere with study outcomes.
  • Participant who has used/applied any personal care products (for example, lotions, sunscreens, sunless tanners) and/or topical medications in/on the test area within 24 hours of Study Day 1.
  • Participant who is unwilling to cease use of personal care products (for example, lotions, sunscreens, sunless tanners) and/or topical medications in/on the test area for the duration of the study.
  • Participant with any known communicable disease(s) (for example, Human Immunodeficiency Virus [HIV], Sexually Transmitted Diseases [STD's], Hepatitis B, Hepatitis C, and so on)
  • Participant with skeletal protrusions and/or extreme areas of curvature in the test area.
  • Participant with a medical treatment/vaccination (other than the Covid-19 vaccination) planned during the study, which would make them ineligible, place them at undue risk, or confound the outcome of the study, per the discretion of the PI.
  • Participant who has undergone any surgical procedure in the last 12 months.
  • Participant who has undergone chemical or physical treatment procedures in the test area within the last 12 months.
  • Planned hospitalization during the study.
  • Participant who exceeds a weight limit of 300 pounds due to equipment limitations.
  • Participant with any condition that might confound the study results, increase the risk associated with participation, or interfere with study participation.
  • Female participant who is pregnant, planning to become pregnant during the study, or breastfeeding (self-reported).
  • Participant with any visible sunburn or suntan in test area.
  • Participant with visible sun damage, scarring or tattoos in the test area that would interfere with study participation.
  • Participant with any sun exposure and/or use of an artificial tanning lamp on the test area within 2 months of Study Day 1.
  • Participant who is unwilling to avoid sun exposure and/or cease use of an artificial tanning lamp on the test area for the duration of the study.
  • Participant who has participated in any clinical study involving UV exposure within the last 2 months, or any other type of clinical study within the last 1 month.
  • Participant who is an employee/contractor or immediate family member of the PI, study site or Sponsor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05085327


Locations
Layout table for location information
United States, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27101
Sponsors and Collaborators
HALEON
  Study Documents (Full-Text)

Documents provided by HALEON:
Layout table for additonal information
Responsible Party: HALEON
ClinicalTrials.gov Identifier: NCT05085327    
Other Study ID Numbers: 218003
First Posted: October 20, 2021    Key Record Dates
Results First Posted: March 25, 2024
Last Update Posted: March 25, 2024
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoint and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sunscreening Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Dermatologic Agents